Sangui BioTech: Positive Outlook after Weak Fourth Quarter / Cost Cutting Initiated

WITTEN, Germany--(BUSINESS WIRE)--

According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of less than USD130,000 in the course of its financial year 2015, ended June 30, 2015. In the financial year 2014 revenues amounted to USD133,470. Revenues in the fourth quarter came in at around USD11,000 (Q4/2014: USD43,729).

Royalties from the licensing agreement regarding the wound treatment product Granulox engrossed by SanguiBioTech GmbH in the operating currency EUR, however, increased by 34.4% in the 2015 financial year.

SanguiBioTech GmbH has reacted to the sluggish top line development by starting a new round of cost cutting involving personnel expenses and office space as well as reducing patent expenses by giving up marginal patents, in particular those protecting the cosmetics business.

According to preliminary information provided by global licensee SastoMed GmbH Granulox sales are expected to increase again slightly in the current quarter (ending September 30) and more significantly in the December quarter.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies SGBI. Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges SBH. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150827005047/en/